Search results for "Administration"

showing 10 items of 5106 documents

Efficacy and safety comparison of two amoxicillin administration schedules after third molar removal. A randomized, double-blind and controlled clini…

2009

Objective: The aim of this comparative double-blind, prospective, randomized, clinical trial was to evaluate two amoxicillin administration patterns. The first was a short prophylactic therapy and the second a long postoperative regimen. Study Design: The study population consisted of 160 patients who underwent mandibular third molar extraction. Patients were randomized into two equal groups. In group 1, 2 grams of amoxicillin were administered 1 hour before the procedure and 1 gram 6 hours after surgery. In group 2, patients received 1 gram of amoxicillin 6 hours after surgery followed by 1 gram every 8 hour for 4 days. All patients received the same number of tablets thanks to the use of …

AdultMalemedicine.medical_specialtyPlaceboDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawmedicineHumansProspective StudiesAntibiotic prophylaxisProspective cohort studyGeneral DentistryPostoperative Carebusiness.industryAmoxicillinPain scaleAmoxicillinAntibiotic Prophylaxis:CIENCIAS MÉDICAS [UNESCO]MolarSurgeryAnti-Bacterial AgentsClinical trialRegimenOtorhinolaryngologyAnesthesiaUNESCO::CIENCIAS MÉDICASTooth ExtractionSurgeryFemalebusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

2006

1. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1117-25. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M. Operative Unit of Gastroenterology, St Camillo-Forlanini Hospital, Rome, Italy. prantera@tin.it BACKGROUND: Clinicians often employ antibiotics in Crohn's disease. Rifaximin is active against bacteria frequently found in the intestinal mucosa of Crohn's disease patients. AIM: To evaluate the difference in efficacy between once and twice/daily oral administration of rifaximin and placebo in the treatment of active Crohn's …

AdultMalemedicine.medical_specialtyPlacebo-controlled studyCIPROFLOXACINPlaceboGastroenterologyInflammatory bowel diseaseDrug Administration ScheduleRifaximinPlaceboschemistry.chemical_compoundCrohn DiseaseDouble-Blind MethodIntestinal mucosaINFLAMMATORY-BOWEL-DISEASE C-REACTIVE PROTEIN ULCERATIVE-COLITIS METRONIDAZOLE CIPROFLOXACIN MANAGEMENT RECURRENCE DIARRHEA ANTIBODY MODERATEInternal medicinemedicineMANAGEMENTHumansPharmacology (medical)RECURRENCEAntibacterial agentCrohn's diseaseChi-Square DistributionHepatologybusiness.industryGastroenterologyMiddle Agedmedicine.diseaseRifamycinsUlcerative colitisDIARRHEAC-REACTIVE PROTEINAnti-Bacterial AgentsSurgeryRifaximinTreatment OutcomechemistryULCERATIVE-COLITISANTIBODYMETRONIDAZOLEAcute Diseaserifaximin.crohn's diseaseMODERATEFemalebusinessINFLAMMATORY-BOWEL-DISEASE
researchProduct

Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial.

2000

Antipsychotic efficacy and side effects of the selective sigma ligand EMD 57445 (panamesine) were investigated in 12 patients (6 males, 6 females) who met DSM-III-R criteria for schizophrenia. A 4-week open clinical study revealed only modest effects of EMD 57445 and its metabolites on positive and negative symptoms of schizophrenia. Extrapyramidal and other side effects were moderate, although a significant increase in mild dyskinetic movements was found. Five patients, four of whom were females, completed the trial. Dropouts were mainly due to treatment failure. Antipsychotic effects were significantly greater in female than male patients.

AdultMalemedicine.medical_specialtyPsychosismedicine.medical_treatmentSigma receptorPanamesineDrug Administration ScheduleBasal Ganglia DiseasesPiperidinesInternal medicinemental disordersmedicineHumansReceptors sigmaAntipsychoticOxazolesBiological PsychiatryBiotransformationAgedPsychiatric Status Rating ScalesDose-Response Relationship DrugMiddle Agedmedicine.diseaseClinical trialPsychiatry and Mental healthEndocrinologyTreatment OutcomeTolerabilityDopamine receptorSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychologyAntipsychotic AgentsPsychiatry research
researchProduct

Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassemia major patients: a randomised clinical trial

2009

A multicentre randomized open-label trial was designed to assess the effectiveness of long-term sequential deferiprone–deferoxamine (DFO–DFP) versus DFP alone to treat thalassaemia major (TM). DFP at 75 mg/kg, divided into three oral daily doses, for 4 d/week and DFO by subcutaneous infusion (8–12 h) at 50 mg/kg per day for the remaining 3 d/week was compared with DFP alone at 75 mg/kg, administered 7 d/week during a 5-year follow-up. The main outcome measures were differences between multiple observations of serum ferritin concentrations. Secondary outcomes were survival analysis, adverse events, and costs. Consecutive thalassaemia patients (275) were assessed for eligibility; 213 of these…

AdultMalemedicine.medical_specialtyRandomizationAdolescentPyridonesAdministration OralKaplan-Meier EstimateDeferoxamineInfusions SubcutaneousIron Chelating AgentsGastroenterologylaw.inventionYoung Adultchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansDeferiproneAdverse effectDecreased serum ferritinSurvival analysisbusiness.industryHematologySurgeryClinical trialDeferoxamineChelation thalassaemia clinical trials red blood cell disorders iron overload.Treatment OutcomechemistryFerritinsThalassemiaDrug Therapy CombinationFemalebusinessDeferiproneFollow-Up Studiesmedicine.drug
researchProduct

Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet (R)) versus calcipotriol (Daivonex (R)) in the treatment of …

2007

Objective: A clinical trial was performed to evaluate the efficacy, speed of response, side effects and quality of life of patients treated with calcipotriol/betamethasone dipropionate (Dovobet (R)) for 4 weeks followed by maintenance with calcipotriol for 8 weeks (group A) versus calcipotriol (Daivonex (R)) alone for 12 weeks (group B) for the treatment of psoriasis. Materials and methods: A total of 150 patients were enrolled and randomized to groups A and B. PASI and Skindex-29 were considered the outcome measures. Results: Ninety-six patients completed the trial. At weeks 2 and 4, both groups showed a significant clinical improvement compared to baseline; group A demonstrated a higher c…

AdultMalemedicine.medical_specialtyRandomizationAdolescentskindex-29medicine.drug_classBetamethasone dipropionatecalcipotriol/betamethasone dipropionate; Dovobet; calcipotriol. Daivonex; psoriasis vulgaris; clinical trialDermatologyAdministration CutaneousBetamethasoneSeverity of Illness IndexDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled trialCalcitriolcalcipotriolo/betametasone dipropionatolawPsoriasisInternal medicinepasimedicineHumansPsoriasiscalcipotriolo; calcipotriolo/betametasone dipropionato; pasi; psoriasi; skindex-29CalcipotriolcalcipotriolopsoriasiAgedAged 80 and overAnalysis of Variancebusiness.industrycalcipotriol calcipotriol/betamethasone dipropionate PASI psoriasis Skindex-29 two-compound productMiddle Agedmedicine.diseaseSurgeryClinical trialDrug CombinationsTreatment OutcomechemistryQuality of LifeCorticosteroidBetamethasoneFemaleDermatologic Agentsbusinessmedicine.drug
researchProduct

"Dry biopsies" with spraying of dilute epinephrine optimize biopsy mapping of long segment Barrett's esophagus

2008

BACKGROUND AND STUDY AIMS: For surveillance of Barrett’s esophagus random stepwise four-quadrant biopsy (4QB) is recommended for detecting macroscopically occult neoplasias. Thorough performance of the systematic protocol is commonly hampered by poor visibility due to oozing from biopsy sites. Topical application of dilute epinephrine may prevent bleeding by vasoconstriction of superficial microvessels and might therefore enable ”dry biopsy” sampling. The aim of this study was to examine the safety and efficacy of spraying dilute epinephrine for optimal 4QB mapping of Barrett’s esophagus. PATIENTS AND METHODS: In this prospective, double-blind trial 40 patients with known long segment Barre…

AdultMalemedicine.medical_specialtyRandomizationEpinephrinemedicine.medical_treatmentAdministration TopicalBarrett EsophagusEsophagusDouble-Blind MethodBiopsymedicineHumansVasoconstrictor AgentsSampling (medicine)EsophagusSalineAgedAged 80 and overmedicine.diagnostic_testbusiness.industryEsophageal diseaseBiopsy NeedleGastroenterologyMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureEpinephrineBarrett's esophagusFemaleEsophagoscopybusinessmedicine.drug
researchProduct

OASIS-HT: design of a pharmacogenomic dose-finding study.

2005

Experimental evidence and observations in humans strongly support an interactive role of mutated α-adducin, sodium (Na+)/potassium (K+)-adenosine triphosphatase (ATPase) activity and endogenous ouabain in Na+homeostasis and the pathogenesis of hypertension. The Ouabain and Adducin for Specific Intervention on Sodium in HyperTension (OASIS-HT) trial is an early Phase II dose-finding study, which will be conducted across 39 European centers. Following a run-in period of 4 weeks without treatment, eligible patients will be randomized to one of five oral doses of rostafuroxin consisting of 0.05, 0.15, 0.5, 1.5, or 5.0 mg/day. Each dose will be compared to a placebo in a double-blind crossover e…

AdultMalemedicine.medical_specialtyRandomizationTime FactorsSystolic hypertensionMolecular ConformationAdministration OralBlood PressurePharmacologyPlaceboOuabainDrug Administration ScheduleDouble-Blind MethodRisk FactorsInternal medicineGeneticsClinical endpointMedicineHumansAndrostanolsOuabainAntihypertensive AgentsPharmacologyCross-Over StudiesDose-Response Relationship Drugbusiness.industryMiddle Agedmedicine.diseaseCrossover studyBlood pressureEndocrinologyTreatment OutcomeHypertensionMolecular MedicineCalmodulin-Binding ProteinsFemalebusinessHomeostasismedicine.drugPharmacogenomics
researchProduct

A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in…

2004

Summary Background  Topical application of clobetasol-17-propionate has been diffusely reported as an efficacious therapy in atrophic/erosive oral lichen planus (OLP), without exposing the patient to systemic side-effects. However, prolonged contact and respective topical effects on the oral mucosa should be avoided. Objectives  The aim of the present study was to evaluate efficacy and compliance of new lipid microspheres loaded with 0·025% of clobetasol propionate (formulation A) compared with a commonly used formulation (a sort of dispersion of a lipophilic ointment in a hydrophilic phase) with the same amount of drug (formulation B) in the topical treatment of OLP. Patients and methods  …

AdultMalemedicine.medical_specialtyRandomizationVisual analogue scaleAdministration TopicalChemistry PharmaceuticalAnti-Inflammatory AgentsDermatologyDosage formlaw.inventionOintmentsDrug Delivery SystemsRandomized controlled triallawMedicineHumansSingle-Blind MethodOral mucosaGlucocorticoidsAgedAged 80 and overClobetasolbusiness.industryMiddle Agedmedicine.diseaseDermatologyLipidsMicrospheresRegimenmedicine.anatomical_structureclobetasol propionate delivery lipid microspheres oral lichen planusPatient ComplianceOral lichen planusFemaleClobetasol propionatebusinessmedicine.drugLichen Planus OralThe British journal of dermatology
researchProduct

Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized s…

2020

AbstractIron deficiency anemia is among the most frequent causes of disability. Intravenous iron is the quickest way to correct iron deficiency, bypassing the bottleneck of iron intestinal absorption, the only true mechanism of iron balance regulation in human body. Intravenous iron administration is suggested in patients who are refractory/intolerant to oral iron sulfate. However, the intravenous way of iron administration requires several precautions; as the in-hospital administration requires a resuscitation service, as imposed in Europe by the European Medicine Agency, it is very expensive and negatively affects patient’s perceived quality of life. A new oral iron formulation, Sucrosomi…

AdultMalemedicine.medical_specialtyResuscitationIntravenous sodium ferrigluconateAnemiaCost-Benefit AnalysisHigh dosesAdministration OralHigh dose030204 cardiovascular system & hematologyGastroenterologyFerric CompoundsIntestinal absorption03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRefractoryInternal medicineOral Sucrosomial ironMedicineHumans030212 general & internal medicineFerrous CompoundsProspective StudiesAgedAged 80 and overHematologyAnemia Iron-Deficiencybusiness.industryHematologyGeneral MedicineIron deficiencyMiddle Agedmedicine.diseaseIron sulfatechemistryIron-deficiency anemiaIron deficiency anemiaHematinicsAdministration IntravenousFemaleOriginal ArticleRefractoriness/intolerance to oral iron sulfatebusiness
researchProduct

Estimation of pharmacokinetic parameters of lithium from saliva and urine

1974

The salivary and urinary excretion of lithium was studied in three healthy male sub;ects after oral administration of two or three different doses. In all individuals the concentration of lithium in salivary fluid was found to be 2.2 to 3.3 times as high as the concentration in plasma. In each sub;ect the saliva:plasma concentration ratio remained constant over more than a 100 fold concentration range for at least 3 months. This ratio was not markedly affected by about tenfold changes in saliva flow rate. Thus, pharmacokinetic parameters obtained from salivary excretion data are in agreement with those obtained from plasma concentration and urinary excretion rate data, and renal clearance o…

AdultMalemedicine.medical_specialtySalivaTime FactorsSalivary ExcretionMetabolic Clearance RateAdministration OralUrineLithiumKidneyUrinary excretionPharmacokineticsOral administrationInternal medicinemedicineHumansPharmacology (medical)SalivaPharmacologyChemistrySpectrophotometry AtomicDiurnal rhythmsCircadian RhythmKineticsEndocrinologyCreatinineRegression AnalysisSalivationHalf-LifeClearanceClinical Pharmacology & Therapeutics
researchProduct